About 21 results found for searched term "JAK1-IN-8" (0.128 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M49577 | JAK1-IN-8 | JAK |
| JAK1-IN-8, a potent JAK1 inhibitor (IC50<500 nM), compound 28, extracted from patent WO2016119700A1. | ||
| M1700 | Momelotinib (CYT387) | JAK |
| LM-1149; Momelotinib; CYT 11387 | ||
| Momelotinib (CYT387) is a small-molecule, ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 and 18 nM respectively. | ||
| M1787 | INCB18424 | JAK |
| Ruxolitinib | ||
| Ruxolitinib (INCB018424) is a first-in-class, potent, selective JAK1/2 inhibitor with an IC50 of 3.3 nM/2.8 nM. It is more than 130-fold more selective for JAK1, JAK2, and JAK3 than JAK3. It can be used in studies related to pemphigus, myelofibrosis and vitiligo. | ||
| M2912 | Pacritinib | JAK |
| SB1518 | ||
| Pacritinib (SB1518) is an effective mutant inhibitor of wild-type JAK2 and JAK2V617F with IC50 of 23 nM and 19 nM, respectively. Pacritinib also inhibited FLT3 and its mutant FLT3D835Y with IC50 of 22 nM and 6 nM, respectively. | ||
| M3030 | S-Ruxolitinib | JAK |
| S-Ruxolitinib; INCB18424 | ||
| S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. | ||
| M11227 | FM-479 | JAK |
| Fm-479 was a negative control of FM-381 and showed no activity against JAK3 or other kinases. Fm-381 is a potent covalent reversible inhibitor of JAK3 targeting unique Cys909. For JAK3, FM-381 was 410, 2700 and 3600 times more selective than JAK1, JAK2 and TYK2 with IC50 of 127 pM. | ||
| M4912 | GLPG0634 analogue | JAK |
| GLPG0634 analogue is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively. | ||
| M5827 | Oclacitinib maleate | JAK |
| PF-03394197 | ||
| Oclacitinib is a novel inhibitor of JAK family members with IC50 ranging from 10 to 99 nM and JAK1-dependent cytokines with IC50 ranging from 36 to 249 nM, which did not inhibit a panel of 38 non-JAK kinases. | ||
| M5944 | Ruxolitinib phosphate | JAK |
| INCB018424 phosphate; INCB 018424 phosphate; INCB-018424 phosphate; Ruxolitinib | ||
| Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. | ||
| M7551 | Solcitinib | JAK |
| GSK-2586184; GLPG-0778 | ||
| Solcitinib is an oral, competitive, potent, and selective JAK1 inhibitor with an IC50 value of 9.8 nM, which is 11,55, and 23 times more selective than JAK2, JAK3, and TYK2. Solcitinib can be used in studies of psoriasis. | ||
| M8090 | PF-04965842 | JAK |
| Abrocitinib | ||
| Abrocitinib is an orally active and selective JAK1 inhibitor with an IC50 value of 29 nM. Abrocitinib reversibly inhibits JAK1 kinase by blocking its ATP-binding site. Abrocitinib (PF-04965842) inhibited TYK2 activity (IC50, 1.253 μM) and phosphorylation of STAT1, STAT3, and STAT5 after stimulation. It can be used in the study of autoimmune diseases. | ||
| M27991 | Pacritinib hydrochloride | JAK |
| SB-1518 hydrochloride | ||
| Pacritinib hydrochloride is a potent inhibitor of both wild-type JAK2 (IC50=23 nM) and JAK2V617F mutant (IC50=19 nM). Pacritinib hydrochloride also inhibits FLT3 (IC50=22 nM) and its mutant FLT3D835Y (IC50=6 nM). Pacritinib hydrochloride can be used for the research of acute myeloid leukemia (AML) and myelofibrosis (MF). | ||
| M28195 | JAK-IN-1 | JAK |
| JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1. | ||
| M28893 | JAK3-IN-1 | JAK |
| JAK3-IN-1 is a potent, selective and orally active JAK3 inhibitor with an IC50 of 4.8 nM. JAK3-IN-1 shows over 180-fold more selective for JAK3 than JAK1 (IC50 of 896 nM) and JAK2 (IC50 of 1050 nM). | ||
| M30500 | RO8191 | Interferon-α/β/γ |
| CDM-3008; RO4948191 | ||
| RO8191 (CDM-3008), an imidazonaphthyridine compound, is an orally active and potent interferon (IFN) receptor agonist. RO8191 directly binds to IFNα/β receptor 2 (IFNAR2) and activates IFN-stimulated genes (ISGs) expression and JAK/STAT phosphorylation. RO8191 shows antiviral activity against both HCV and EMCV with an IC50 of 200 nM for HCV replicon. RO8191 is a cccDNA modulator (CDM) through interferon-like activity and has anti-HBV activity. | ||
| M41707 | JAK3-IN-14 | JAK |
| JAK3-IN-14 is a potent JAK3 inhibitor, with IC50 values of 38 and 600 nM for JAK3 and JAK2, respectively. | ||
| M49566 | Itacnosertib | JAK |
| Itacnosertib (TP-0184) is both inhibitor to JAK2, ACVR1 (ALK2) and ALK5 as described in WO2014151871. | ||
| M49576 | JAK1-IN-4 | JAK |
| JAK1-IN-4 is a potent and selective JAK1 inhibitor, with IC50s of 85 nM, 12.8 μM and >30 μM for JAK1, JAK2, and JAK3, respectively. | ||
| M49579 | JAK-2/3-IN-1 | JAK |
| JAK-2/3-IN-1 is a potent JAK-2 and JAK-3 inhibitor extracted from patent US8163732B2, compound 46, has Kis of <250 nM for both isoforms. | ||
| M49592 | JAK3-IN-11 | JAK |
| JAK3-IN-11 , a potent, noncytotoxic, irreversible, orally active JAK3 inhibitor with IC50 value of 1.7 nM, has excellent selectivity (>588-fold compared to other JAK isoforms), covalently bind to the ATP-binding pocket in JAK3. | ||
| M49593 | JAK3-IN-12 | JAK |
| JAK3-IN-12 is a highly potent JAK3 inhibitor with IC50 values of 9.5 nM, 18 nM and 42 nM for JAK3, JAK1 and JAK2, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
